Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?

✍ Scribed by Sanjeet Pakrasi; Alan Thomas; Urs P. Mosimann; David A. Cousins; Debbie Lett; David J. Burn; John T. O'Brien; Ian G. McKeith

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 44 KB
• Volume: 21
• Category: Article
• ISSN: 0885-6230
• DOI: 10.1002/gps.1547

✦ Synopsis

Abstract

Introduction

There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB.

Method

We conducted an open label trial with donepezil involving 16 patients with LBD when the dose was reduced and treatment stopped over 4 weeks. Another 7 patients were given a trial of an increased dose of donepezil (15 mg) to resolve re‐emergent neuropsychiatric symptoms.

Results

The slow discontinuation protocol was well tolerated in advanced DLB. Five of the seven patients given a trial of a higher dose of donepezil were rated as clinically improved after 12 weeks treatment.

Conclusion

Cholinesterase inhibitors can be discontinued slowly in advanced DLB. Increasing the dose of donepezil may be of benefit to some patients with DLB who experience a recurrence in their neuropsychiatric symptoms. Copyright © 2006 John Wiley & Sons, Ltd.